Mymetics Valuation

Is MYMX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MYMX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MYMX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MYMX's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for MYMX?

Key metric: As MYMX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MYMX. This is calculated by dividing MYMX's market cap by their current revenue.
What is MYMX's PS Ratio?
PS Ratio0.0003x
Sales€533.00k
Market Cap€134.92

Price to Sales Ratio vs Peers

How does MYMX's PS Ratio compare to its peers?

The above table shows the PS ratio for MYMX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.0008x
INFI.Q Infinity Pharmaceuticals
0.00003xn/aUS$90.0
ARDS Aridis Pharmaceuticals
0.000002xn/aUS$53.0
DMTK.Q DermTech
0.000002xn/aUS$35.0
GNCA.Q Genocea Biosciences
0.003xn/aUS$5.9k
MYMX Mymetics
0.0003xn/aUS$151.0

Price-To-Sales vs Peers: MYMX is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (0x).


Price to Sales Ratio vs Industry

How does MYMX's PS Ratio compare vs other companies in the US Biotechs Industry?

129 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.9.6x21.4%
MYMX Mymetics
0.0003xn/aUS$151.00
GILD Gilead Sciences
4x2.4%US$112.40b
BIIB Biogen
2.4x1.3%US$23.01b
MYMX 0.0xIndustry Avg. 9.6xNo. of Companies129PS01632486480+
129 CompaniesEstimated GrowthMarket Cap
Industry Avg.9.6x28.3%
MYMX Mymetics
0.0003xn/aUS$151.00
No more companies

Price-To-Sales vs Industry: MYMX is good value based on its Price-To-Sales Ratio (0x) compared to the US Biotechs industry average (12.4x).


Price to Sales Ratio vs Fair Ratio

What is MYMX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MYMX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.0003x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MYMX's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies